Literature DB >> 16631114

Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus.

Shinichiro Mine1, Yosuke Okada, Takahisa Tanikawa, Chie Kawahara, Takahiro Tabata, Yoshiya Tanaka.   

Abstract

Increased monocyte recruitment into subendothelial space in atherosclerotic lesions is one of the hallmarks of diabetic angiopathy. The aim of this study was to determine the state of peripheral blood monocytes in diabetes associated with atherosclerosis. Diabetic patients treated with/without an oral hypoglycemic agent and/or insulin for at least 1 year were recruited (n=106). We also included 24 non-diabetic control subjects. We measured serum levels of monocyte chemoattractant protein (MCP)-1, fasting plasma glucose (FPG), HbA1c, total cholesterol, triglyceride, body mass index (BMI), high sensitivity CRP (hs-CRP) and evaluated CCR2, CD36, CD68 expression on the surface of monocytes. Serum MCP-1 levels were significantly (p<0.05) higher in diabetic patients than in normal subjects. In diabetic patients, serum MCP-1 levels correlated significantly with FPG, HbA1c, triglyceride, BMI, and hs-CRP. The expression levels of CCR2, CD36, and CD68 on monocytes were significantly increased in diabetic patients and were more upregulated by MCP-1 stimulation. Our data suggest that elevated serum MCP-1 levels and increased monocyte CCR2, CD36, CD68 expression correlate with poor blood glucose control and potentially contribute to increased recruitment of monocytes to the vessel wall in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631114     DOI: 10.1016/j.bbrc.2006.03.197

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis.

Authors:  Sarah L Ullevig; Qingwei Zhao; Debora Zamora; Reto Asmis
Journal:  Atherosclerosis       Date:  2011-06-17       Impact factor: 5.162

2.  Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome.

Authors:  Huiqing Li; Xiuling Deng; Zhenqiong Li; Changqing Luo; Jianshe Liu; Yumei Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

3.  Cardio-ankle vascular index is linked to deranged metabolic status, especially high HbA1c and monocyte-chemoattractant-1 protein, in predialysis chronic kidney disease.

Authors:  Mehmet Mert; Belda Dursun; Ahmet Baki Yağcı; Ayşen Çetin Kardeşler; Hande Şenol; Süleyman Demir
Journal:  Int Urol Nephrol       Date:  2019-11-26       Impact factor: 2.370

4.  Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP.

Authors:  Craig W Younce; Kangkai Wang; Pappachan E Kolattukudy
Journal:  Cardiovasc Res       Date:  2010-03-30       Impact factor: 10.787

Review 5.  The next generation of therapeutics for chronic kidney disease.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Nat Rev Drug Discov       Date:  2016-05-27       Impact factor: 84.694

Review 6.  Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway.

Authors:  Pappachan E Kolattukudy; Jianli Niu
Journal:  Circ Res       Date:  2012-01-06       Impact factor: 17.367

7.  Role of CCR2 in the Development of Streptozotocin-Treated Diabetic Cardiomyopathy.

Authors:  Xin Tan; Lizhi Hu; Zhiping Shu; Long Chen; Xiangrao Li; Meng Du; Dan Sun; Xiaoxiang Mao; Shan Deng; Kai Huang; Fengxiao Zhang
Journal:  Diabetes       Date:  2019-08-22       Impact factor: 9.461

8.  Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Abdelnoor Michael; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir Ø Andersen
Journal:  Cardiovasc Diabetol       Date:  2010-09-02       Impact factor: 9.951

9.  Resveratrol inhibits expression and binding activity of the monocyte chemotactic protein-1 receptor, CCR2, on THP-1 monocytes.

Authors:  John P Cullen; David Morrow; Ying Jin; Nicholas von Offenberg Sweeney; James V Sitzmann; Paul A Cahill; Eileen M Redmond
Journal:  Atherosclerosis       Date:  2007-05-17       Impact factor: 5.162

10.  CCL2/CCR2 augments the production of transforming growth factor-beta1, type 1 collagen and CCL2 by human CD45-/collagen 1-positive cells under high glucose concentrations.

Authors:  Akinori Hara; Norihiko Sakai; Kengo Furuichi; Yoshio Sakai; Motohiro Takeya; Richard Bucala; Naofumi Mukaida; Yoh Takuwa; Kouji Matsushima; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-04-06       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.